While small gains were made in the hip and trauma business, the company reported larger declines in the spine and knee lines. Here is the breakdown for Johnson & Johnson’s orthopedic sales:
1. Orthopedics overall: J&J reported $2.2 billion in third quarter sales, flat from the same period last year. For the nine months end, orthopedic sales were down 0.4 percent, driven by slow international sales.
2. Hips: Hip sales were up 1.5 percent for the quarter, hitting $328 million. The U.S. market drove hip sales with 2.6 percent growth over the same period last year. For the nine months end, hip sales were up 1.9 percent to $1 billion.
3. Knees: A huge drop — 6.8 percent — in international knee sales drove the 3.4 percent decline in worldwide knee sales for the third quarter. J&J reported $348 million in knee sales for the quarter and $1.1 billion for the nine months end, which was a 0.3 percent drop from the first nine months of 2016. U.S. knee sales dropped 1.3 percent in the quarter.
4. Trauma: Worldwide trauma sales were up 3.9 percent for the third quarter, hitting $662 million. As opposed to the company’s knee sales, international trauma sales jumped 6.5 percent in the quarter to $264 million. For the nine months end, trauma sales grew 1.7 percent to nearly $2 billion.
5. Spine and other: U.S. spine sales suffered in the third quarter, declining 5.2 percent year-over-year. The drop in U.S. sales was partially offset by 1.8 percent growth in international spine and other sales, but worldwide sales were down 2.2 percent in the quarter, reaching just $918 million. For the nine months end, spine and other sales dropped 2.6 percent to $2.8 billion.
More articles on orthopedic devices:
Arthrex to build $30M manufacturing plant in SC: 5 insights
Amedica earns extension to demonstrate Nasdaq listing compliance
NuVasive earns expanded FDA clearance for TLX interbody system
